Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

908
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
908
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

924
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
924
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

941
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
941
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias01:16

ECG Interpretation of Arrhythmias I: Sinus Arrhythmias

203
Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
203
Structure of Lipids03:38

Structure of Lipids

87.5K
Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic...
87.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Precision Medicine for Electrocardiogram Interpretation: Clinical Relevance, Challenges, and Advances.

Reviews in cardiovascular medicine·2026
Same author

Impact of Timing of Atrial Fibrillation Ablation on AF Recurrence and Clinical Outcomes in Patients With HFpEF and HFrEF.

Journal of cardiovascular electrophysiology·2025
Same author

Palpitations After Leadless Pacemaker Implantation.

Circulation·2025
Same author

Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy.

Circulation. Arrhythmia and electrophysiology·2025
Same author

Impact of Diagnosis to Ablation Time on Recurrence of Atrial Fibrillation and Clinical Outcomes After Catheter Ablation: A Systematic Review and Meta-Analysis With Reconstructed Time-to-Event Data.

Circulation. Arrhythmia and electrophysiology·2025
Same author

Mitigation of pacing-induced cardiomyopathy with superficial right ventricular mid-septal pacing: A long-term retrospective comparison with apical pacing.

Journal of cardiovascular electrophysiology·2024

相关实验视频

Updated: Jun 17, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.7K

欧米茄-3 脂肪酸和心律失常

Mason D Marcus1, Mark S Link1

  • 1Department of Medicine, Division of Cardiology, UT Southwestern Medical Center, Dallas, TX.

Circulation
|August 5, 2024
PubMed
概括
此摘要是机器生成的。

欧米茄-3脂肪酸 (n-3PUFAs) 在心律方面显示出不同的结果. 虽然一些研究表明有好处,但高剂量可能会增加心房动 (AF) 的风险,但机制尚不清楚.

关键词:
心房动多可萨赫萨诺酸乙酸脂肪酸,欧米茄三

更多相关视频

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice
06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

3.6K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K

相关实验视频

Last Updated: Jun 17, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.7K
Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice
06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

3.6K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K

科学领域:

  • 心脏病学
  • 药理学
  • 生物化学

背景情况:

  • 欧米茄3多不和脂肪酸 (n-3PUFA) 已被研究为促和抗不律的作用.
  • 早期研究表明n-3PUFA可以预防心脏突然死亡和心房动 (AF).
  • 然而,最近的大型随机试验对抗心律失常的益处产生了矛盾的结果.

研究的目的:

  • 评估n-3PUFA对心律失常的复杂且往往相互矛盾的作用,特别是心律失常.
  • 评估目前关于n-3PUFA补充剂在心血管预防和AF治疗中的有效性和安全性的临床证据.
  • 研究特定的n-3PUFA配方和剂量的潜在促节律作用.

主要方法:

  • 临床前研究和人类临床试验的审查,包括随机对照试验 (RCT).
  • 对研究中度和高剂量的n-3PUFAs (包括eicosapentaenoic acid (EPA) 和docosahexaenoic acid (DHA)) 进行心血管预防的大型当代RCT数据的分析.
  • 与对照组相比,在接受n-3PUFA的参与者中检查了与事件AF相关的发现.

主要成果:

  • 累积的证据不支持n-3PUFA补充剂用于术后的AF或二次AF预防.
  • 与安慰剂相比,几项大型试验表明,高剂量的n-3PUFA (伊可萨乙烯或EPA+DHA) 对发生的AF有微小而显著的剂量依赖性增加.
  • 在单疗法和混合疗法中观察到这些前节律的发现,但潜在的机制仍然未知.

结论:

  • 对于预防心律失常,特别是心律失常的n-3PUFA的临床效用是不确定的,并可能引起争议.
  • 高剂量的n-3PUFA补充剂,包括特殊配方如icosapent ethyl,可能会增加发 AF 的风险.
  • 需要进一步的研究,以阐明EPA,DHA及其代谢物的复杂促和阻节律机制,并确定患有较高风险的患者子组.